A Phase 1 SBIR was awarded to advance the development of a long duration, novel opioid medical countermeasure for use by Department of Defense Service Members in far-forward deployed settings.
News
Tarik Soliman Selected to Pitch at the Life Sciences Summit, Sponsored by the NCI
Dr. Soliman was selected by the National Cancer Institute for their Investor Initiatives program, a once-yearly competitive program that connects SBIR-funded companies with potential investors and strategic partners to continue the commercialization efforts initially funded by NCI. He received executive coaching on his presentation, EXT418 for the Treatment of Cancer Cachexia, in preparation for pitching at the Emerging Company Showcase at the Life Sciences Summit held in New York City. Extend Biosciences also received financial assistance from NCI to cover the presentation and registration costs for the conference.
A Phase 1 SBIR Grant from NINDS was Received by Extend Biosciences
The grant will be used to fund proof-of-concept work and efficacy studies on a long-acting ghrelin for the treatment of peripheral neuropathy.
Extend Biosciences receives an SBIR supplemental award
The company received an Administrative Supplement award from NCI to further the development of the long-acting ghrelin asset for the treatment of cancer cachexia.
The US Patent and Trademark office awards Extend Biosciences with a mark for D-VITylation
Extend Biosciences’ trademark registration has been issued for the name of their platform technology, D-VITylation.
Founder Laura Hales speaks on a panel about Extend Biosciences’ non-dilutive funding path
Laura Hales was one of three panelists at an event sponsored by ENET titled “SBIR grants and non-dilutive funding to bootstrap your startup company”.
Extend Biosciences is awarded a Phase II SBIR grant from NIDDK
Extend Biosciences’ long-acting PTH molecule will advance through IND-enabling studies with a Phase II grant from NIDDK.
NIDDK awards Extend Biosciences with a Phase I grant
Extend Biosciences was awarded a Phase I SBIR grant to advance their long-acting insulin molecule for the treatment of diabetes.
Founder Laura Hales speaks on a panel sponsored by The Capital Network
At an event titled “SBIR – America’s Largest Seed Fund”, Extend Biosciences founder Laura Hales spoke about her experience winning SBIR grants.
A Panel on Women Entrepreneurs in STEM features founder Laura Hales
Founder Laura Hales was one of four female entrepreneurs featured on a panel titled “She Prevailed – The Secretes to Start-up Success in STEM from Women Entrepreneurs”. The panel was sponsored by AWIS and also featured Patrice Milos, Ailis Tweed-Kent, and Teresa Nelson, and was moderated by Joanne Kamens.